title: Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio.
abstract: The neutrophil/lymphocyte (N/L) ratio at diagnosis has been shown to be a prognostic factor for survival in solid tumors. The N/L ratio at diagnosis as a prognostic factor for non-Hodgkin lymphoma (NHL) has not been studied. Thus, we studied N/L ratio at diagnosis as a prognostic factor for patients with diffuse large B-cell lymphoma (DLBCL)treated with R-CHOP. From 2000 until 2007, 255 consecutive DLBCL patients, originally diagnosed, treated with R-CHOP, and followed at Mayo Clinic, Rochester, were included in this study. With a median follow-up of 4.0 years (range: 0.3-9.0 years), patients with an N/L ratio<3.5 at diagnosis experienced a superior overall survival (OS) and progression-free survival (PFS) compared with those patient with an N/L ratio ≥ 3.5 at diagnosis. The median OS was not reached versus 6.8 years, P < 0.0001; and the median PFS was not reached versus 3.3 years, P < 0.0001, respectively. Multivariate analysis showed N/L ratio to be an independent prognostic factor for OS and PFS. This study suggests that baseline N/L ratio at diagnosis is a simple, inexpensive,standardized prognostic factor to assess clinical outcomes in DLBCL patients treated with R-CHOP.
authors.affiliation: Division of Hematology/Department of Medicine, Mayo College of Medicine, 200 First Street SW, Rochester, MN 55905, USA. porrata.luis@mayo.edu
authors.forename: Luis F
authors.initials: LF
authors.lastname: Porrata
authors.forename: Kay
authors.initials: K
authors.lastname: Ristow
authors.forename: Thomas
authors.initials: T
authors.lastname: Habermann
authors.forename: David J
authors.initials: DJ
authors.lastname: Inwards
authors.forename: Ivana N
authors.initials: IN
authors.lastname: Micallef
authors.forename: Svetomir N
authors.initials: SN
authors.lastname: Markovic
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count; D008214:Lymphocytes / Q000473:pathology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality*; D015999:Multivariate Analysis; D009504:Neutrophils / Q000473:pathology*; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone